The Zhitong Finance App learned that on Wednesday, biotech company Attovia Therapeutics (ATTO.US) officially landed on the NASDAQ and closed up 28.82% on the first day of listing to $21.9. The IPO price is $17. Established in 2022, Attovia's core technology “ATTOBODY” platform is a biotechnology platform based on biparatopic nanoantibodies (biparatopic nanobody), obtained an exclusive license from Alamar Biosciences (ALMR.US). The platform enables the development of multi-specific antibody therapies targeting complex immune targets.

The company currently has three drugs under development, of which ATTO-1310 is the company's core asset. The drug has completed phase I clinical trial administration for healthy volunteers and patients with chronic pruritus and atopic dermatitis. As a bispecific antibody targeting IL-13 and IL-31, ATTO-2306 is expected to achieve more comprehensive efficacy coverage in the field of atopic dermatitis. As a tri-specific antibody, ATTO-1091 also targets the three popular immune targets of TL1A, IL-23, and integrin α4β7, pointing to the huge inflammatory bowel disease market.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.